Development of a 90‐Minute Integrated Noninvasive Urinary Assay for Bladder Cancer Detection
暂无分享,去创建一个
M. Meng | Y. Lotan | W. Sexton | A. Weizer | Russell Higuchi | K. Mach | J. Liao | J. Bridge | D. Scherr | B. Goldfarb | Jun Zhang | A. Hiar | B. Egerdie | Mandy L. Y. Sin | Leena McCann | M. Woods | E. Wallace | K. Jansz | J. Zadra | E. Wong | M. Satya | Huilin Wei | Shoichiro Ohta | Mohammed Taha
[1] Y. Lotan,et al. Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study , 2017, The Journal of urology.
[2] John D Seigne,et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. , 2016, The Journal of urology.
[3] Y. Lotan,et al. Current Status of Urinary Biomarkers for Detection and Surveillance of Bladder Cancer. , 2016, The Urologic clinics of North America.
[4] J. Witjes,et al. Gene expression test for the non-invasive diagnosis of bladder cancer: A prospective, blinded, international and multicenter validation study. , 2016, European journal of cancer.
[5] A. Pendergast,et al. The Emerging Role of ABL Kinases in Solid Tumors. , 2015, Trends in cancer.
[6] Andreas Böhle,et al. Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1 and CIS) , 2014 .
[7] Y. Jeng,et al. Annexin A10 is an immunohistochemical marker for adenocarcinoma of the upper gastrointestinal tract and pancreatobiliary system , 2013, Histopathology.
[8] M. Dalphin,et al. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria. , 2012, The Journal of urology.
[9] M. Burset,et al. Gene Expression Signature in Urine for Diagnosing and Assessing Aggressiveness of Bladder Urothelial Carcinoma , 2010, Clinical Cancer Research.
[10] J. Witjes,et al. Recurrence, Progression, and Follow-Up in Non–Muscle-Invasive Bladder Cancer , 2009 .
[11] J. Fitzpatrick,et al. Urinary insulin‐like growth factor 2 identifies the presence of urothelial carcinoma of the bladder , 2009, BJU international.
[12] T. Kwast,et al. Urine markers for bladder cancer surveillance: a systematic review. , 2005 .
[13] William A. Mcmillan,et al. Technology for automated, rapid, and quantitative PCR or reverse transcription-PCR clinical testing. , 2005, Clinical chemistry.
[14] D. Polsky,et al. Detection of circulating cancer cells expressing uroplakins and epidermal growth factor receptor in bladder cancer patients , 2004, International journal of cancer.
[15] J. Southgate,et al. Human uroplakin lb gene structure and promoter analysis. , 2002, Biochimica et biophysica acta.
[16] T. Tammela,et al. Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. , 2002, European urology.
[17] T. Sano,et al. Expression of corticotropin-releasing hormone messenger ribonucleic acid in human pituitary corticotroph adenomas associated with proliferative potential. , 2000, The Journal of clinical endocrinology and metabolism.
[18] S. Wilczynski,et al. Expression of insulin-like growth factor (IGF)-II in human prostate, breast, bladder, and paraganglioma tumors , 1998, Cell and Tissue Research.
[19] Russell Higuchi,et al. Kinetic PCR Analysis: Real-time Monitoring of DNA Amplification Reactions , 1993, Bio/Technology.